Nafsika Afentou1,2, Johan Jarl1, Ulf-G Gerdtham1,3,4, Sanjib Saha1. 1. Health Economics Unit, Department of Clinical Science (Malmö) Lund University Lund Sweden. 2. Health Economics Unit Institute of Applied Health Research, University of Birmingham Birmingham United Kingdom. 3. Centre for Economic Demography Lund University Lund Sweden. 4. Department of Economics Lund University Lund Sweden.
Abstract
BACKGROUND: Parkinson's disease (PD) management comprises of drug treatments, surgery, and physical activity/occupational therapies to relieve PD's symptoms. The aim of this study is twofold; first, to appraise recent economic evaluation studies on PD management in order to update the existing knowledge; and second, to facilitate decision making on PD management by assessing the cost-effectiveness of all types of PD interventions. METHODS: A systematic search for studies published between 2010 and 2018 was conducted. The inclusion and exclusion of the articles were based on criteria relevant to population, intervention, comparison, outcomes, and study design (PICO). The reporting quality of the articles was assessed according to Consolidated Health Economic Evaluation Reporting Standards. RESULTS: Twenty-eight articles were included, 10 of which were evaluations of drug treatments, 10 deep brain stimulation (DBS), and eight physical/occupational therapies. Among early-stage treatments, Ti Ji dominated all physical activity interventions; however, its cost-effectiveness should be further explored in relation to its duration, intensity, and frequency. Multidisciplinary interventions of joint medical and nonmedical therapies provided slightly better health outcomes for the same costs. In advanced PD patients, adjunct drug treatments could become more cost-effective if introduced during early PD and, although DBS was more cost-effective than adjunct drug therapies, the results were time-bound. CONCLUSIONS: Conditionally, certain PD interventions are cost-effective. However, PD progression differs in each patient; thus, the cost-effectiveness of individually tailored combinations of interventions that could provide more time in less severe disease states and improve patients' and caregivers' quality of life, should be further explored.
BACKGROUND: Parkinson's disease (PD) management comprises of drug treatments, surgery, and physical activity/occupational therapies to relieve PD's symptoms. The aim of this study is twofold; first, to appraise recent economic evaluation studies on PD management in order to update the existing knowledge; and second, to facilitate decision making on PD management by assessing the cost-effectiveness of all types of PD interventions. METHODS: A systematic search for studies published between 2010 and 2018 was conducted. The inclusion and exclusion of the articles were based on criteria relevant to population, intervention, comparison, outcomes, and study design (PICO). The reporting quality of the articles was assessed according to Consolidated Health Economic Evaluation Reporting Standards. RESULTS: Twenty-eight articles were included, 10 of which were evaluations of drug treatments, 10 deep brain stimulation (DBS), and eight physical/occupational therapies. Among early-stage treatments, Ti Ji dominated all physical activity interventions; however, its cost-effectiveness should be further explored in relation to its duration, intensity, and frequency. Multidisciplinary interventions of joint medical and nonmedical therapies provided slightly better health outcomes for the same costs. In advanced PD patients, adjunct drug treatments could become more cost-effective if introduced during early PD and, although DBS was more cost-effective than adjunct drug therapies, the results were time-bound. CONCLUSIONS: Conditionally, certain PD interventions are cost-effective. However, PD progression differs in each patient; thus, the cost-effectiveness of individually tailored combinations of interventions that could provide more time in less severe disease states and improve patients' and caregivers' quality of life, should be further explored.
Authors: Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl Journal: Mov Disord Date: 2004-09 Impact factor: 10.338
Authors: Annika E Spottke; Martin Reuter; Olaf Machat; Bernhard Bornschein; Sonja von Campenhausen; Karin Berger; Rudolf Koehne-Volland; Jürgen Rieke; Alexander Simonow; Dirk Brandstaedter; Uwe Siebert; Wolfgang H Oertel; Gudrun Ulm; Richard Dodel Journal: Pharmacoeconomics Date: 2005 Impact factor: 4.981
Authors: T Keränen; S Kaakkola; K Sotaniemi; V Laulumaa; T Haapaniemi; T Jolma; H Kola; A Ylikoski; O Satomaa; J Kovanen; E Taimela; H Haapaniemi; H Turunen; A Takala Journal: Parkinsonism Relat Disord Date: 2003-01 Impact factor: 4.891